Summit Biosciences Management Team
Left to right: Richard Cohen, Ted Marcuccio, Sonia Egbert, and Gregory Plucinski

Edwin A. Cohen

Founder, Chief Executive Officer and Chairman

Prior to founding Summit, Mr. Cohen was the Founder, CEO and Chairman of Intranasal Therapeutics, Inc. and an original investor in ScinoPharm (Taiwan), after a successful career in the generic pharmaceutical industry. Most notably, he is founder and former Chairman and CEO of Barr Laboratories, Inc., a pharmaceutical company that traded on the NYSE and grew to over $3 billion in annual sales before its acquisition by Teva in 2008 for $7.5 billion. He also co-founded Davis Edwards Pharmacal Corporation, one of the first companies to manufacture and promote multisource drugs. He is a founding member of the Board of Directors of the Generic Pharmaceutical Industry Association, the predecessor to the Association for Accessible Medicines, and a founding member and Executive Board member of the National Association of Pharmaceutical Manufacturers. A graduate of Fordham University, Mr. Cohen received an Honorary Doctor of Science Degree and was appointed to the Board of Trustees of this institution.

Gregory G. Plucinski

Chief Operating Officer

Mr. Plucinski has more than 27 years of experience in pharmaceutical research, development and manufacturing operations. Prior to joining Summit Biosciences in 2009, Mr. Plucinski served as Vice President of Pharmaceutical Manufacturing Operations at Intranasal Therapeutics, Inc. ("ITI"), where he led the design, construction, start-up, validation and the day-to-day operations of the manufacturing plant. While at ITI, he also led the product development team to the successful development and manufacturing of ITI's lead products, midazolam nasal spray for epileptic seizure and hydromorphone nasal spray for acute pain. This work and others led to patent filings which are currently pending or issued with the USPTO. Prior to joining ITI in 2002, Mr. Plucinski has held various senior operational management positions in both start-up and high growth-organizations such as Dey, LP (Merck, KGaA subsidiary) where he led teams to develop and manufacture a diverse array of pharmaceutical and biological products, including generic nasal spray and inhalation products. Mr. Plucinski holds a B.S. in Biology from the University of Wisconsin - Whitewater and an M.B.A. from the University of Kentucky.

Sonia L. Egbert

Chief Accounting Officer

Ms. Egbert has more than 26 years of experience in the fields of accounting and finance, which includes working with start-up pharmaceutical companies. Prior to joining Summit Biosciences in 2009, Ms. Egbert served as the Controller at Intranasal Therapeutics, Inc. ("ITI") where she was responsible for Board of Director and investor reporting; cash management; banking, insurance and investor relations; accounting controls; budgeting and forecasting. Prior to ITI, Ms. Egbert was Treasurer and Controller at a successful start-up web-based transportation company. Ms. Egbert also held various director-level positions at a fortune 200 transportation company (BNSF) in the finance, accounting and forecasting and planning departments where she was involved with merger transactions, SEC reporting, managing revenue and capital budgets. Ms. Egbert worked for Deloitte & Touche at various levels in their audit group in both the Minneapolis and Dallas offices. Ms. Egbert holds a Bachelor of Business Administration degree from the University of Wisconsin Eau-Claire and is a CPA.

Ted A. Marcuccio

Chief Business Officer

Mr. Marcuccio has more than 15 years of executive experience with leading companies in the pharmaceutical industry. He has played an instrumental role in a wide range of corporate transactions as a business development executive and former investment banker. He has a vast network of contacts in the healthcare and life sciences industry and strong relationships in the capital markets. Prior to Summit Biosciences, Mr. Marcuccio led government and commercial development and alliance management for Meridian Medical Technologies, Inc., a subsidiary of Pfizer Inc., which specialized in emergency use pharmaceuticals delivered with its proprietary auto-injector technology. He was Vice President and Head of Licensing and Business Development for Meridian's former parent company, King Pharmaceuticals, Inc., until its acquisition by Pfizer in 2011. Previous to joining King in 2004, he was Vice President of Vaccines Business Development for Baxter International. Mr. Marcuccio completed an undergraduate degree and a professional certification in accounting (CMA) and earned an MBA from the McCombs School of Business at the University of Texas at Austin.